Physician profile
Jason S Yip
NPI 1487862066
$4,082.33
in general payments reported to CMS, 2019-2025
26 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $910 · 2020: $293 · 2021: $933 · 2022: $993 · 2023: $293 · 2024: $380 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $914.54 | 2019-2025 | |
| Gilead Sciences, INC. | $678.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $611.02 | 2019-2025 | Xifaxan |
| Conmed Corporation | $351.14 | 2019 | |
| Celgene Corporation | $272.65 | 2021-2023 | Zeposia |
| Pfizer INC. | $153.25 | 2019-2024 | |
| Boston Scientific Corporation | $150.35 | 2024-2025 | General - Endochoice |
| Ironwood Pharmaceuticals, INC | $118.97 | 2020-2023 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $109.69 | 2021 | |
| Janssen Biotech, INC. | $106.58 | 2022-2024 | Tremfya, Stelara |
| Genzyme Corporation | $91.39 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $80.18 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.74 | 2021-2023 | Gattex |
| Enterra Medical, INC. | $63.59 | 2023 | |
| Ardelyx, INC. | $52.84 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $37.17 | 2022 | |
| Allergan, INC. | $36.08 | 2019 | |
| Qol Medical, LLC | $33.15 | 2022 | |
| W. L. Gore & Associates, INC. | $27.92 | 2020-2022 | |
| Intra-Sana Laboratories | $26.78 | 2022-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Redhill Biopharma INC. | $22.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $22.07 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $15.29 | 2021 | |
| Evoke Pharma, INC. | $14.89 | 2020 | |
| Shionogi INC | $13.93 | 2019 | |
| Endogastric Solutions, INC | $9.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Yip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.